- Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
- Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
- Terns Pharmaceuticals Announces Leadership Changes
- Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
- Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
- Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
- Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
- Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
- Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
More ▼
Key statistics
On Friday, Terns Pharmaceuticals Inc (TERN:NSQ) closed at 5.90, 80.98% above the 52 week low of 3.26 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.12 |
---|---|
High | 6.12 |
Low | 5.85 |
Bid | 5.69 |
Offer | 6.32 |
Previous close | 6.14 |
Average volume | 843.79k |
---|---|
Shares outstanding | 64.67m |
Free float | 63.52m |
P/E (TTM) | -- |
Market cap | 397.10m USD |
EPS (TTM) | -1.26 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼